
    
      The purpose of this protocol is to provide a mechanism to collect Clinical Data from those
      babies who participated in the primary Study 64,185-06-2(W)(WS)(ISNHP) "An Open-Label Study
      Of The Safety And Clinical Pharmacology Of StanateÂ® In Infants At-Risk For Exchange
      Transfusion". Data on long-term impact of Stannsoporfin on the physical, neurological,
      neurodevelopmental, biochemical, metabolic and hematopoietic profiles of the children will be
      collected at 9 and 18 months, 3, 6 and 9 years after Stannsoporfin administration
    
  